Last reviewed · How we verify
CSF-1
CSF-1 is a recombinant human colony-stimulating factor 1 that promotes the growth and differentiation of myeloid progenitor cells.
CSF-1 is a recombinant human colony-stimulating factor 1 that promotes the growth and differentiation of myeloid progenitor cells. Used for Immune reconstitution and myeloid cell recovery in immunocompromised patients.
At a glance
| Generic name | CSF-1 |
|---|---|
| Also known as | Qlosi, pilocarpine HCl 0.4% |
| Sponsor | Orasis Pharmaceuticals Ltd. |
| Drug class | Cytokine |
| Target | CSF-1 receptor (c-FMS) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
CSF-1 (macrophage colony-stimulating factor) binds to the CSF-1 receptor on hematopoietic progenitor cells, stimulating their proliferation and differentiation into macrophages and other myeloid lineage cells. This mechanism is intended to support immune cell recovery and function, particularly in contexts of immune suppression or deficiency.
Approved indications
- Immune reconstitution and myeloid cell recovery in immunocompromised patients
Common side effects
- Bone pain
- Fever
- Fatigue
- Injection site reactions
Key clinical trials
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (PHASE2)
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (PHASE2)
- A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients (PHASE2)
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (PHASE2)
- Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma (PHASE2)
- Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma (PHASE1)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSF-1 CI brief — competitive landscape report
- CSF-1 updates RSS · CI watch RSS
- Orasis Pharmaceuticals Ltd. portfolio CI